NF155, CNTN1 & CASPR1: What Do They Mean for Treatment?

If your blood tests positive for NF155, CNTN1, or CASPR1 antibodies, it may support a diagnosis of an autoimmune nodopathy ^[1][2]. While these conditions look and feel very similar to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), they are driven by a slightly different biological process. A positive test result alone does not establish a diagnosis; it must be interpreted alongside your symptoms, nerve-conduction studies, and a thorough specialist evaluation ^[2][3]. However, identifying one of these antibodies is an important piece of information because it can guide which treatments your care team might consider.

How Are These Antibodies Different?

In typical CIDP, the immune system mistakenly attacks the myelin sheath, which is the protective insulation wrapping around your nerves. In autoimmune nodopathies, the immune system targets specific proteins located at the nodes of Ranvier (the tiny gaps between the myelin sheaths) or the paranodes (the areas immediately next to the gaps) ^[1]. NF155, CNTN1, and CASPR1 are structural proteins at these junctions.

When antibodies attack these targets, the connection between the myelin and the nerve fiber is disrupted, impairing the nerve’s ability to send electrical signals normally ^[1][4].

Clues from Your Symptoms (Phenotypes)

While everyone’s experience is unique, certain symptoms have been associated with specific antibodies in observational studies:

• NF155: Often associated with a younger age of onset, sensory ataxia (loss of coordination and balance), tremor, and weakness that is more pronounced in the hands and feet ^[5][6].
• CNTN1: Can appear in older adults and often has a more rapid (acute or subacute) onset. In some cases, it is associated with a kidney condition called membranous nephropathy ^[7][8].
• CASPR1: Associated with rapidly progressive weakness, pain, gait disturbances, and sometimes involvement of the cranial nerves (which control the face and eyes) ^[9][10].

How Antibody Status Changes Treatment

The presence of these antibodies can change how your body responds to standard therapies. Many reported cases involving these antibodies belong to an immune subclass called IgG4 (though not all do), which can help explain why they often respond differently to certain medications ^[10][11].

Intravenous Immunoglobulin (IVIg)

IVIg is a cornerstone treatment for standard CIDP, but observational studies suggest it may be less effective for many patients with these specific antibodies ^[5][12]. In one observational cohort, 39% of antibody-positive nodopathy patients showed improvement with IVIg, compared to 80% of antibody-negative CIDP patients ^[12]. This does not mean IVIg will definitely fail for you—some antibody-positive patients still benefit. You should never stop or change your IVIg treatment without your treating neurologist’s guidance.

Other Treatment Options

If you do not respond to IVIg or corticosteroids, your specialist might discuss other options. These treatments are often based on observational case series rather than large, robust randomized trials ^[13]:

• Plasma Exchange (PLEX): A process that temporarily filters circulating antibodies out of your blood, which has shown benefit for some patients who do not respond to IVIg ^[14][15]. It carries potential risks, including blood-pressure changes, bleeding, and infection.
• Rituximab: An off-label, targeted therapy that depletes B-cells to reduce ongoing antibody production. It is frequently considered by specialists for progressing or treatment-resistant cases and has shown benefit in observational cohorts ^[6][10][2]. Important risks include infection and hepatitis B reactivation, requiring careful screening, vaccination planning, and monitoring.
• Corticosteroids: Response to steroids can be variable; some patients improve while others do not experience a benefit ^[16][8].

Diagnosis and Testing Considerations

Antibody testing can be complex. Because false positives can occur, unexpected positive results typically need confirmation by a specialized laboratory using a second assay method ^[17][18]. Blood (serum) testing is generally better validated than spinal fluid testing for these specific antibodies.

What if your test is negative?
A negative result simply means no detectable antibodies were found on that specific assay. A negative result does not rule out CIDP or an autoimmune nodopathy, as these antibodies are only present in a minority of patients, and the diagnosis remains primarily clinical ^[19][20].

Safety and Urgent Care Guidance

Receiving a rare-antibody result can be confusing, but it provides information for planning your care rather than a fixed prediction of your future. Always seek urgent medical attention if you experience rapidly worsening weakness, new difficulty breathing or swallowing, inability to walk safely, or significant new facial or eye involvement.

If you have CNTN1 antibodies, your doctor may consider screening for kidney involvement. Because standard kidney function tests might remain normal even when protein is being lost, screening usually involves a urinalysis or urine-protein test ^[7]. Report any sudden swelling (edema), foamy urine, or rapid weight gain to your medical team.